Key Financial Results
Fiscal Year Ended March 31, 2026 (FY26)
- Sales: ₹4290 crore, flat versus the comparable period last year.
- Profit After Tax (PAT): ₹857 crore, up 19% versus the comparable period last year.
- PAT Growth Drivers: Improvement attributed to product mix, productivity, and efficiency.
Fourth Quarter Ended March 31, 2026 (Q4 FY26)
- Sales: ₹941 crore, down 5% versus the year-ago quarter.
- Profit After Tax (PAT): ₹153 crore, down 2% versus the year-ago quarter.
Financial Year Comparability Note
The company changed its Financial Year from July 1 – June 30 to April 1 – March 31, effective last year. Therefore, the previous financial year (2024-25) covered a 9-month period from July 1, 2024, to March 31, 2025. All performance comparisons in this release are versus an indexed comparable 12-month period (April 1, 2024, to March 31, 2025). Performance versus the actual 9-month past fiscal is stated to be not comparable.
Dividend Declaration
- The Board of Directors has recommended a final dividend of ₹60 per Equity Share for FY26.
- This is subject to the approval of shareholders at the ensuing 62nd Annual General Meeting.
- An interim dividend (including a one-time special dividend) of ₹195 per share was already paid.
- The total dividend payout for the fiscal year, subject to approval, will be ₹255 per share.
Management Commentary and Business Update
V Kumar, Managing Director, stated the company continues to strengthen its focus on consumers through innovation across its feminine care and healthcare portfolios. The strategy is anchored in a focused portfolio, superiority across product performance, packaging, brand communication, retail execution and value, productivity, constructive disruption, and an agile organization.
Key Initiatives and Product Updates
- Targeted Investments: Made in consumer-centric innovations and strengthening go-to-market capabilities.
- Feminine Care (Whisper): Amplified communication to increase consumer awareness for the Whisper Period Panty. Upgraded formulations for Whisper Choice and Whisper Bindazzz Nights.
- Healthcare (Vicks): The upgraded Vicks VapoRub formulation with Eucalyptus Oil, Menthol, and Camphor is noted for delivering All-Night Relief for Uninterrupted Sleep.
- The company is confident these initiatives address changing consumer needs and position it for long-term competitiveness.
Corporate Social Responsibility (CSR)
- The company continued to contribute to the P&G group's flagship CSR program, P&G Shiksha.
- Since 2005, the program has supported thousands of schools and communities, impacting over 1 crore children from underserved areas.